BACKGROUND: Ginseng extracts, known to enhance bodily functions including learning and memory, were reported to have in vitro neuroprotective activity in vitro. Here We demonstrate the possible therapeutic effects of ginsenosides on the cell culture model of Alzheimer's Disease (AD). We tested whether Rb1 or Rg1 , major components of ginseng saphonins, protects neuronal cells from the toxic effect of beta-amyloid (Abeta), which is regarded to be the main neurotoxic substrate in the AD. METHOD: B103 cells, rat brain-derived neuronal cells, were cultured and the extent of neuroprotective effects of ginsenosides on the cytotoxicity induced by exogenous Abeta25-35 was were measured by MTT assay. RESULTS: Treatment of Rb1 and Rg1 at various concentrations (l0nM, 50nM, and 1 micrometer, respectively) in B103 cells did not show any dose-dependent neurotoxic effects. Rg1 (1 micrometer) significantly blocked the neurotoxic effect of Abeta2 5 - 3 5 (50 micrometer)(P<0.05). Rb1 at concentration of 1 micrometer also had some neuroprotective effects, but not as effective as Rg1 . These neuroprotective effects are comparable to the one of estrogen (1.8nM). CONCLUSIONS: This experiment suggests the potential beneficial effects of ginseng in the treatment of AD.
Alzheimer Disease ; Amyloid* ; Animals ; Cell Culture Techniques ; Estrogens ; Ginsenosides ; Learning ; Memory ; Neurons ; Neuroprotective Agents ; Panax ; Rats

Tumor DNA content measured by flow cytometry may be a predictor in the prognosis of epithelial ovarian cancer, but the results have been inconsistent. It is recognized that these conflicting results are at least partly due to the variation of DNA content between the samples from the same patient(i.e., intratumoral DNA heterogeneity). The purposes of this retrospective study were to investigate the frequency and the nature of DNA heterogeneity in epithelial ovarian cancer and to evaluate the prognostic significance of DNA heterogenetiy itself. Thirty-two patients with stage II to IV epithelial ovarian cancer who were managed at Asan Medical Center between May 1993 and April 1996 were analysed. Measurements of the nuclear DNA content were performed on samples from primary and metastatic lesion using paraffin embedded archival tissues by Epics(Coulter Inc.) flow cytometry. In two cases, the metastatic tumor was minute and did not reveal a separable peak on repeated examination. DNA heterogeneity was defined as different ploidy pattern or difference of the DNA indices than 0.15 between primary and metastatic tumors. DNA heterogeneity was found in 11 cases(36.7%), and the number of cases with homogeneous diploid and that with homogeneous aneuploid tumor were 5(16.7%) and 14(46.7%) respectively. In evaluation of prognostic significance of DNA heterogeneity using correlation with serum CA 125 level after second course of chemotherapy and residual tumor size after cytoreductive surgery among these three groups, the patients with DNA heterogeneity were considered to show intermediate prognosis between those with homogeneous diploid and homogeneous aneuploid tumor. In conclusion, DNA heterogeneity in epithelial ovarian cancer is considerable in frequency and may have prognostic value.
Aneuploidy ; Chungcheongnam-do ; Diploidy ; DNA* ; Drug Therapy ; Flow Cytometry ; Humans ; Neoplasm, Residual ; Ovarian Neoplasms* ; Paraffin ; Ploidies* ; Population Characteristics* ; Prognosis ; Retrospective Studies

Background: In this study, we aimed to investigate the recent trends for health care indicators including maternal mortality ratio, infant mortality rate, under-five mortality rate, life expectancy, years of life lost, and healthcare resources in South Korea, North Korea, Germany, Russian Federation, Mongolia, Vietnam, China, Czech Republic, Poland, and Hungary. Methods: We used data from five sources: World Health Organization, Federal Institute for Population Research, World Bank, Organization for Economic Cooperation and Development health statistics, and national statistics. Results: In the early 1990s, health indicators continued to improve in countries that switched to the health insurance system, but the gap widened in North Korea as health indicators worsened. Conclusion The establishment of a sustainable health care system after unification of the Korean peninsula requires substantial changes in the health care system and efforts to improve the health of North Koreans.

Mutations in the tumor suppressor p53 gene are the most frequently observed genetic lesions in human cancers. It seems that wild type p53 does significant role on growth and differentiation of normal cells, Mutations and allelic loss of the p53 gene are thought to be a cause of tumor development and to be correlated with the prognostic factors in various human cancers such as breast, ovary and lung cancer. Mutant p53 proteins have a prolonged half-life and can be detected by immunohistochemistry. In case of GTD(gestational trophoblastic disease), although the mutation of p53 gene mutation was revealed to be very rare, the overexpression of p53 in immunohistochemical staining has been reported in wide range of discrepancy and its role or prognostic significance in GTD is uncertain. This study is performed to define the status of p53 overexpression in GTD and to evaluate the correlations between p53 overexpression and prognostic factors of GTD. THE RESULTS WERE AS FOLLOWS: 1. p53 overexpression was detected in none of normal placental tissue, in 58.3%(14/24) of hydatidiform mole, in 15%(6/8) of invasive mole, in 75%(3/4) of choriocarcinoma, and in 100%(1/1) of placental site trophoblastic tumor, and showed significant difference between normal placenta and GTD. We could not find any difference of the p53 overexpression between benign group(H-mole) of GTD and malignant one(invasive mole, choriocarcinoma, and placental site trophoblastic tumor) 2. In H-mole, low-risk group showed significantly higher prevalence of p53 overexpression than high-risk group did. In malignant group, there is no difference in the prevalence of p53 overexpression between early(FIGO stage I) and late(II- IV)stage-diseases, but the prevalence of p53 overexpression of low-risk group is slightly higher than that of high-risk group although we failed to find statistical significance. In conclusion, the high prevalence of p53 overexpression in GTD suggests that p53 may have a certain role in the pathogenesis of GTD or at least represent generalized DNA damage or genetic instability of GTD. And the higher prevalence of p53 overexpression in low-risk group suggests that accumulation of wild-type p53 may be related with favorable prognosis in GTD.
Breast ; Choriocarcinoma ; DNA Damage ; Female ; Genes, p53 ; Gestational Trophoblastic Disease* ; Half-Life ; Humans* ; Hydatidiform Mole ; Hydatidiform Mole, Invasive ; Immunohistochemistry ; Loss of Heterozygosity ; Lung Neoplasms ; Ovary ; Placenta* ; Pregnancy ; Prevalence ; Prognosis ; Trophoblastic Tumor, Placental Site ; Trophoblasts

No abstract available.
Carcinoma, Transitional Cell* ; Fallopian Tubes* ; Female

Opsoclonus is the involuntary, repetitive, rapid conjugate ocular movements occurring in all directions that are irregular in amplitude and frequency. The cause of opsoclonus are idiopathic, paraneoplastic or postinfectious. Opsoclonus of the postinfectious origin often accompanies other abnormal movements such as tremor, myoclonus and ataxia, and shows a relatively benign course with good response to steroid. Six patients who suffered from myalgia, chilling, fever, cough and generalized weakness fior one to two weeks prior to the admission, experienced visual disturbance, gait unsteadiness and clumsiness of the upper extremities,, Prominent opsoclonus, tremulous movements of trunk and limbs, and intermittent myoclonus were observed. These symptoms markedly improved several days following the use of ACTH or dexametasone.
Adrenocorticotropic Hormone ; Adult* ; Ataxia ; Cough ; Dyskinesias ; Extremities ; Fever ; Gait ; Humans ; Myalgia ; Myoclonus ; Ocular Motility Disorders* ; Tremor ; Upper Extremity

Opsoclonus is the involuntary, repetitive, rapid conjugate ocular movements occurring in all directions that are irregular in amplitude and frequency. The cause of opsoclonus are idiopathic, paraneoplastic or postinfectious. Opsoclonus of the postinfectious origin often accompanies other abnormal movements such as tremor, myoclonus and ataxia, and shows a relatively benign course with good response to steroid. Six patients who suffered from myalgia, chilling, fever, cough and generalized weakness fior one to two weeks prior to the admission, experienced visual disturbance, gait unsteadiness and clumsiness of the upper extremities,, Prominent opsoclonus, tremulous movements of trunk and limbs, and intermittent myoclonus were observed. These symptoms markedly improved several days following the use of ACTH or dexametasone.
Adrenocorticotropic Hormone ; Adult* ; Ataxia ; Cough ; Dyskinesias ; Extremities ; Fever ; Gait ; Humans ; Myalgia ; Myoclonus ; Ocular Motility Disorders* ; Tremor ; Upper Extremity

PURPOSE: The study was performed to identify the reality of urinary incontinence (UI) and to evaluate the risk factors developing UI for the patients with Parkinson's disease. MATERIALS AND METHODS: This was the cross-sectional study with interviews using structured questionnaires. The subjects who were 72 patients(male 20, female 52) and their mean age is 70.07+/-20.06(range 54~86) with Parkinson's disease visited the Neurology clinic, from September to November 2005, at one university hospital located in Jeju island. RESULTS: Subjects with restricted mobility were 45, and 13 were in first stage of Hoehn & Yahr stage, 31 were in second stage, 28 were in third stage. Fifty three(73.6%) subjects had experienced UI. Mixed UI was in 32 (44.4%), stress UI 12(16.7%), and urge UI 9(12.5%), respectively. As for risk factors developing UI, female had 1.62 times(OR=1.62, 95% CI=0.47~5.66) more than male, age of 80~86 had 3.20 times(OR=3.20, 95% CI=0.65~15.69) more than age of 54~69, subjects with restricted mobility had 2.75 times(OR=2.75, 95% CI=0.80~9.43) more than subjects without restricted mobility. Group without regular exercise had 2.9 times more than group with regular exercise(OR=2.90, 95% CI=0.92~9.22). Cognitive impairment group had 1.98 times more than normal mental status group(OR=1.98, 95% CI=0.39~9.97). Second stage had 4.91 times(OR=4.91, 95% CI=0.55~43.53) and third stage had 5.68 times(OR=5.68, 95% CI=00.64~50.73) more than first stage in Hoehn and Yahr stage. CONCLUSION: There is a high prevalence(73.6%) of UI in patients with Parkinson's diseases. Mixed UI was the most common type of incontinence. Risk factors developing UI were higher in female, older group, restricted mobility group, group without regular exercise, cognitive impairment group andhigher Hoehn and Yahr stage.
Cross-Sectional Studies ; Female ; Humans ; Male ; Neurology ; Parkinson Disease* ; Surveys and Questionnaires ; Risk Factors ; Urinary Incontinence*

Castleman's disease is a rare non-neoplastic lymphoproliferative disorder of unknown etiology. It is divided into three histologic subtypes; hyaline-vascular(HV), plasma cell(PC) type and mixed type (HV-PC). It has two clinical expressions. The localized form, which presents as a slow growing mass, has a relatively benign clinical course. The multicentric form is multilocated and holds significant morbidity. The mainstay of treatment of the localized form is surgical resection. The multicentric form requires medical treatment comprising prednisolone and other immunosuppressor drugs. The disease in children seems to have a more favorable course than in adults. We report a 13-year- old boy with Castleman's disease of multicentric form who was successfully treated with prednisolone and intravenous immunoglobulin.
Adult ; Child* ; Giant Lymph Node Hyperplasia* ; Humans ; Immunoglobulins ; Lymphoproliferative Disorders ; Male ; Plasma ; Prednisolone*

Background: Non-HLA antibodies, anti-angiotensin II type 1 receptor antibodies (anti-AT1R) and anti-endothelial cell antibodies (AECA), are known to play a role in allograft rejection. We evaluated the role of both antibodies in predicting post-transplant outcomes in low-risk living donor kidney transplantation (LDKT) recipients. Methods: In 94 consecutive LDKT recipients who were ABO compatible and negative for pre-transplant HLA donor-specific antibodies, we determined the levels of anti-AT1Rs using an enzyme-linked immunosorbent assay and the presence of AECAs using a flow cytometric endothelial cell crossmatch (ECXM) assay with pre-transplant sera. Hazard ratio (HR) was calculated to predict post-transplant outcomes. Results: Pre-transplant anti-AT1Rs (≥11.5 U/mL) and AECAs were observed in 36 (38.3%) and 22 recipients (23.4%), respectively; 11 recipients had both. Pre-transplant anti-AT1Rs were a significant risk factor for the development of acute rejection (AR) (HR 2.09; P=0.018), while a positive AECA status was associated with AR or microvascular inflammation only (HR 2.47; P=0.004) throughout the follow-up period. In particular, AECA (+) recipients with ≥11.5 U/mL anti-AT1Rs exhibited a significant effect on creatinine and estimated glomerular filtration rate (P<0.001; P=0.028), although the risk of AR was not significant. Conclusions Pre-transplant anti-AT1Rs and AECAs have independent negative effects on post-transplant outcomes in low-risk LDKT recipients. Assessment of both antibodies would be helpful in stratifying the pre-transplant immunological risk, even in low-risk LDKT recipients.